Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Preferred Stock Liabilities (2022 - 2023)

Gyre Therapeutics (GYRE) has disclosed Preferred Stock Liabilities for 4 consecutive years, with $64.5 million as the latest value for Q4 2023.

  • Quarterly Preferred Stock Liabilities rose 93.72% to $64.5 million in Q4 2023 from the year-ago period, while the trailing twelve-month figure was $64.5 million through Dec 2023, up 93.72% year-over-year, with the annual reading at $64.5 million for FY2023, 93.72% up from the prior year.
  • Preferred Stock Liabilities for Q4 2023 was $64.5 million at Gyre Therapeutics, up from $33.3 million in the prior quarter.
  • The five-year high for Preferred Stock Liabilities was $64.5 million in Q4 2023, with the low at $33.3 million in Q4 2022.